Teicoplanin Allergy Testing using Autologous Serum (TATAS)

• Research type

  Research Study

• Full title

  Improving THE SENSITIVITY OF Teicoplanin ALLERGY TESTING BY USING Autologous SERUM

• IRAS ID

  345535

• Contact name

  Linda Nel

• Contact email

  linda.nel@uhs.nhs.uk

• Sponsor organisation

  University Hospital Southampton NHS Foundation Trust

• Duration of Study in the UK

  2 years, 11 months, 30 days

• Research summary

  There are very poor positivity rates for skin testing for Teicoplanin in patients who are subsequently shown on testing by exclusion to be allergic to Teicoplanin. These are patients who present via the perioperative allergy service, having had intraoperative anaphylaxis as the index event.

  Addressing the hypothesis of ‘does skin testing fail with teicoplanin allergy because of the need to associate or form a hapten with a plasma protein in order for the patient’s immune system to recognise it as an allergen’, we aim to improve the sensitivity of Teicoplanin allergy testing by using autologous serum for skin tests.
  We will recruit 20 adult patients with history of anaphylaxis under anaesthesia, where teicoplanin has been given. In addition to usual skin testing following standard protocols for all other drugs and substances which would require skin testing as part of standard allergy investigation, we will perform extra tests using autologous serum for this trial. We aim to determine if testing using autologous serum for skin testing yield more positive results as compared to using standard protocol of Teicoplanin Allergy test.

• REC name

  London - Camberwell St Giles Research Ethics Committee

• REC reference

  24/PR/1160

• Date of REC Opinion

  8 Nov 2024

• REC opinion

  Further Information Favourable Opinion